Immunofluorescence Microscopy on the Blood Smear Identifies Patients with Myeloproliferative Neoplasms

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2024 Jul 17

PMID 39020061

Authors

Carlo Zaninetti

Leonard Vater

Lars Kaderali

Carl C Crodel

Tina M Schnoder

Jessica Fuhrmann

Leonard Swensson

Jan Wesche

Carmen Freyer

Andreas Greinacher

Florian H Heidel

Affiliations

Soon will be listed here.

References

Palandri F, Palumbo G, Bonifacio M, Elli E, Tiribelli M, Auteri G . A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis. Cancers (Basel). 2023; 15(20). PMC: 10605705. DOI: 10.3390/cancers15205027. View

Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G . Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. Cancers (Basel). 2023; 15(14). PMC: 10377857. DOI: 10.3390/cancers15143706. View

Nann D, Fend F . Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. Cancers (Basel). 2021; 13(14). PMC: 8303289. DOI: 10.3390/cancers13143528. View

Tefferi A, Lasho T, Guglielmelli P, Finke C, Rotunno G, Elala Y . Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2018; 1(1):21-30. PMC: 5744051. DOI: 10.1182/bloodadvances.2016000216. View

Perner F, Perner C, Ernst T, Heidel F . Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019; 8(8). PMC: 6721738. DOI: 10.3390/cells8080854. View

Zaninetti C, Rivera J, Vater L, Ohlenforst S, Leinoe E, Bockelmann D . Aggregates of nonmuscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia. J Thromb Haemost. 2023; 22(4):1179-1186. DOI: 10.1016/j.jtha.2023.12.007. View

Greinacher A, Pecci A, Kunishima S, Althaus K, Nurden P, Balduini C . Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. J Thromb Haemost. 2017; 15(7):1511-1521. DOI: 10.1111/jth.13729. View

Zaninetti C, Leinoe E, Lozano M, Rossing M, Bastida J, Zetterberg E . Validation of immunofluorescence analysis of blood smears in patients with inherited platelet disorders. J Thromb Haemost. 2023; 21(4):1010-1019. DOI: 10.1016/j.jtha.2022.12.031. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

10.

Verstovsek S, Krecak I, Heidel F, De Stefano V, Bryan K, Zuurman M . Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project. Biomedicines. 2023; 11(7). PMC: 10377437. DOI: 10.3390/biomedicines11071925. View

11.

Guglielmelli P, Lasho T, Rotunno G, Score J, Mannarelli C, Pancrazzi A . The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014; 28(9):1804-10. DOI: 10.1038/leu.2014.76. View

12.

Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A . Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. Hematol Oncol. 2020; 38(3):372-380. DOI: 10.1002/hon.2737. View

13.

Ng Z, Fuller K, Mazza-Parton A, Erber W . Morphology of myeloproliferative neoplasms. Int J Lab Hematol. 2023; 45 Suppl 2:59-70. DOI: 10.1111/ijlh.14086. View